Pyxis Oncology (PYXS) Stock Forecast & Price Target

$3.40

-0.14 (-3.95%)

(As of 10/7/2024 ET)

Pyxis Oncology - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
0

Buy
8

Based on 8 Wall Street analysts who have issued ratings for Pyxis Oncology in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for PYXS.

Consensus Price Target

$9.00
164.71% Upside

According to the 8 analysts' twelve-month price targets for Pyxis Oncology, the average price target is $9.00. The highest price target for PYXS is $12.00, while the lowest price target for PYXS is $7.00. The average price target represents a forecasted upside of 164.71% from the current price of $3.40.

Get the Latest News and Ratings for PYXS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pyxis Oncology and its competitors.

PYXS Analyst Ratings Over Time

Type	Current Forecast 10/8/23 to 10/7/24	1 Month Ago 9/8/23 to 9/7/24	3 Months Ago 7/10/23 to 7/9/24	1 Year Ago 10/8/22 to 10/8/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$9.00	$9.00	$8.80	$10.50
Forecasted Upside	164.71% Upside	157.14% Upside	210.95% Upside	402.39% Upside
Consensus Rating	Buy	Buy	Buy	Buy

[SHOCKING] Crypto Document Leak… (Ad)

Imagine if you could go back to 2009 and buy Bitcoin at $0.01. Or jump to 2015 and grab Ethereum at $0.75. We've created the next best thing: It's called "Crypto Revolution," and it's not just a book… it's your potential ticket to financial time travel.

Download your digital copy of "Crypto Revolution" now (limited-time offer).

PYXS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PYXS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pyxis Oncology Stock vs. The Competition

Type	Pyxis Oncology	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	164.71% Upside	10,695.92% Upside	7.99% Upside
News Sentiment Rating	Neutral News See Recent PYXS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/19/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $7.00	+88.17%
8/16/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00	+104.08%
8/8/2024	Stifel Nicolaus 4 of 5 stars		Initiated Coverage	Buy	$10.00	+219.49%
5/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$10.00	+132.02%
2/9/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$8.00	+115.63%
1/23/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. La. Rosa Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
1/23/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$12.00	+370.59%
11/8/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
4/26/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Slutsky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/23/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$14.00	+536.36%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:36 AM ET.

PYXS Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Pyxis Oncology is $9.00, with a high forecast of $12.00 and a low forecast of $7.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PYXS shares.
: According to analysts, Pyxis Oncology's stock has a predicted upside of 164.71% based on their 12-month stock forecasts.
: Pyxis Oncology has been rated by research analysts at HC Wainwright, Royal Bank of Canada, and Stifel Nicolaus in the past 90 days.
: Analysts like Pyxis Oncology more than other "medical" companies. The consensus rating for Pyxis Oncology is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PYXS compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

320 hedge funds just sold this stock (Ad)

320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are already moving their money… and preparing for even stranger days ahead. Over 320 hedge funds have quietly sold THIS famous stock – to prepare for a dramatic market shift

Get the strange truth from a 50-year Wall Street insider… including the name and ticker of the stock

This page (NASDAQ:PYXS) was last updated on 10/7/2024 by MarketBeat.com Staff

From Our Partners